X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (47862) 47862
Publication (3406) 3406
Newsletter (1451) 1451
Newspaper Article (545) 545
Book Review (473) 473
Book Chapter (354) 354
Dissertation (113) 113
Book / eBook (84) 84
Conference Proceeding (64) 64
Magazine Article (34) 34
Trade Publication Article (23) 23
Transcript (12) 12
Government Document (10) 10
Data Set (8) 8
Web Resource (6) 6
Reference (2) 2
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28341) 28341
animals (16918) 16918
index medicus (14413) 14413
male (13881) 13881
female (10095) 10095
platelet aggregation - drug effects (7385) 7385
hematology (6867) 6867
platelets (6745) 6745
inhibition (6581) 6581
middle aged (6147) 6147
blood platelets - drug effects (6051) 6051
blood platelets - metabolism (5695) 5695
mice (5525) 5525
blood platelets (5496) 5496
rats (5267) 5267
pharmacology & pharmacy (5065) 5065
peripheral vascular disease (5033) 5033
adult (4896) 4896
aged (4571) 4571
platelet aggregation inhibitors - pharmacology (4417) 4417
biochemistry & molecular biology (4372) 4372
cardiac & cardiovascular systems (4340) 4340
activation (3988) 3988
research (3972) 3972
platelet aggregation (3900) 3900
platelet aggregation inhibitors - therapeutic use (3838) 3838
cell biology (3784) 3784
aspirin (3734) 3734
platelet-derived growth factor (3580) 3580
thrombosis (3544) 3544
cells, cultured (3535) 3535
in vitro techniques (3486) 3486
clopidogrel (3446) 3446
dose-response relationship, drug (3351) 3351
aggregation (3324) 3324
expression (2956) 2956
ticlopidine - analogs & derivatives (2774) 2774
time factors (2679) 2679
phosphorylation (2648) 2648
inflammation (2579) 2579
research article (2503) 2503
signal transduction (2451) 2451
treatment outcome (2383) 2383
blood platelets - physiology (2371) 2371
proteins (2360) 2360
medicine (2270) 2270
analysis (2203) 2203
risk factors (2195) 2195
platelet activation (2090) 2090
cells (2087) 2087
rabbits (2071) 2071
platelet aggregation inhibitors - administration & dosage (2052) 2052
oncology (2044) 2044
platelet (2034) 2034
health aspects (2018) 2018
care and treatment (2017) 2017
physiological aspects (2011) 2011
kinetics (1971) 1971
medicine, research & experimental (1928) 1928
cancer (1897) 1897
multidisciplinary sciences (1858) 1858
percutaneous coronary intervention (1856) 1856
physiology (1850) 1850
thrombin (1843) 1843
aspirin - pharmacology (1830) 1830
acute coronary syndromes (1797) 1797
blood (1795) 1795
platelet-aggregation (1783) 1783
atherosclerosis (1720) 1720
adenosine diphosphate - pharmacology (1705) 1705
in-vitro (1683) 1683
platelet activation - drug effects (1669) 1669
receptor (1648) 1648
immunology (1630) 1630
collagen (1623) 1623
disease (1616) 1616
myocardial-infarction (1602) 1602
aspirin - therapeutic use (1582) 1582
apoptosis (1562) 1562
disease models, animal (1558) 1558
drug therapy (1545) 1545
blood platelets - enzymology (1531) 1531
surgery (1531) 1531
ticlopidine - therapeutic use (1515) 1515
in-vivo (1503) 1503
platelet-derived growth factor - pharmacology (1500) 1500
platelet aggregation inhibitors - adverse effects (1491) 1491
angiogenesis (1483) 1483
therapy (1483) 1483
studies (1477) 1477
abridged index medicus (1475) 1475
article (1465) 1465
rats, sprague-dawley (1465) 1465
endothelial-cells (1439) 1439
cardiovascular disease (1415) 1415
gene expression (1379) 1379
nitric oxide (1376) 1376
science (1353) 1353
heart attacks (1339) 1339
thrombin - pharmacology (1333) 1333
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (67) 67
Online Resources - Online (6) 6
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
UofT at Scarborough - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (49076) 49076
German (431) 431
Japanese (222) 222
French (185) 185
Russian (166) 166
Chinese (115) 115
Polish (54) 54
Spanish (51) 51
Italian (33) 33
Korean (26) 26
Portuguese (22) 22
Turkish (18) 18
Hungarian (15) 15
Czech (14) 14
Dutch (8) 8
Swedish (8) 8
Danish (6) 6
Norwegian (6) 6
Slovak (3) 3
Ukrainian (3) 3
Croatian (2) 2
Hebrew (2) 2
Romanian (2) 2
Serbian (2) 2
Bulgarian (1) 1
Greek (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Thrombosis Research, ISSN 0049-3848, 01/2017, Volume 149, pp. 88 - 94
Journal Article
Circulation, ISSN 0009-7322, 2018, Volume 137, Issue 3, pp. 307 - 309
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 09/2018, Volume 118, Issue 9, pp. 1528 - 1534
Abstract The optimal anti-thrombotic therapy for secondary prevention after an acute coronary syndrome is still a matter of debate. While current guidelines... 
Review Article | clinical trials | anti-platelet agents | oral anticoagulants | acute myocardial infarction | CONTROLLED TRIAL | RIVAROXABAN | ASPIRIN | ANTIPLATELET THERAPY | SECONDARY PREVENTION | ANTICOAGULATION | CLOPIDOGREL | ACUTE MYOCARDIAL-INFARCTION | CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1061 - 1075
Journal Article
Circulation, ISSN 0009-7322, 11/2010, Volume 122, Issue 21, pp. 2131 - 2141
Background-Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting. Ticagrelor, a reversible... 
acute coronary syndrome | thrombosis | platelets | myocardial infarction | hemorrhage | 2007 FOCUSED UPDATE | AZD6140 | CARDIAC & CARDIOVASCULAR SYSTEMS | SEGMENT ELEVATION | MANAGEMENT | EVENTS | P2Y RECEPTOR ANTAGONIST | ASPIRIN | ACUTE MYOCARDIAL-INFARCTION | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ASSOCIATION | Purinergic P2Y Receptor Antagonists - administration & dosage | Coronary Thrombosis - epidemiology | Humans | Middle Aged | Male | Angioplasty, Balloon, Coronary | Purinergic P2Y Receptor Antagonists - adverse effects | Adenosine - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Coronary Thrombosis - prevention & control | Ticlopidine - adverse effects | Electrocardiography | Ticlopidine - administration & dosage | Female | Platelet Aggregation Inhibitors - adverse effects | Acute Coronary Syndrome - epidemiology | Hemorrhage - epidemiology | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Adenosine - administration & dosage | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Acute Coronary Syndrome - diagnosis | Aged | Hemorrhage - chemically induced | Usage | Angioplasty | Patient outcomes | Clopidogrel | Drug therapy | Ticagrelor | Health aspects | Heart attack | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
Circulation, ISSN 0009-7322, 09/2010, Volume 122, Issue 11, pp. 1056 - 1067
Background-Reduced renal function is associated with a poorer prognosis and increased bleeding risk in patients with acute coronary syndromes and may therefore... 
clopidogrel | mortality | renal function | acute coronary syndrome | bleeding | myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | MYOCARDIAL-INFARCTION | INSUFFICIENCY | RISK | CLASSIFICATION | IMPACT | EPTIFIBATIDE | PERIPHERAL VASCULAR DISEASE | DYSFUNCTION | CHRONIC KIDNEY-DISEASE | HEMATOLOGY | ARTERY-DISEASE | Kidney Diseases - physiopathology | Outcome Assessment (Health Care) | Ticlopidine - therapeutic use | Humans | Middle Aged | Acute Coronary Syndrome - physiopathology | Male | Adenosine - adverse effects | Adenosine - therapeutic use | Receptors, Purinergic P2Y12 | Ticlopidine - adverse effects | Cardiovascular Diseases - epidemiology | Female | Kidney Diseases - complications | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - physiopathology | Hemorrhage - epidemiology | Hemorrhage - physiopathology | Risk Factors | Kaplan-Meier Estimate | Purinergic P2 Receptor Antagonists | Treatment Outcome | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Aged | Chronic Disease | Aggregation | Usage | Blood platelets | Patient outcomes | Clopidogrel | Drug therapy | Comparative analysis | Health aspects | Heart attack | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
CIRCULATION, ISSN 0009-7322, 07/2012, Volume 126, Issue 4, pp. 455 - 455
Background-Epigenetic programming, dynamically regulated by histone acetylation, is a key mechanism regulating cell proliferation and survival. Little is known... 
TARGET | CELLS | APOPTOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | vorinostat | ACETYLATION | hypertension, pulmonary | epigenesis, genetic | PROLIFERATION | valproic acid | EMERGENCE | ARTERIAL-HYPERTENSION | PROSTATE-CANCER | IN-VIVO | histone deacetylation | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | EXPRESSION | Muscle, Smooth, Vascular - metabolism | Humans | Male | Valproic Acid - pharmacology | Pulmonary Artery - metabolism | Histone Deacetylase 1 - antagonists & inhibitors | Valproic Acid - therapeutic use | Hypertension, Pulmonary - drug therapy | Lung - metabolism | Hydroxamic Acids - pharmacology | Disease Models, Animal | Muscle, Smooth, Vascular - drug effects | Lung - pathology | Cells, Cultured | Rats | Histone Deacetylases - metabolism | Hypertension, Pulmonary - metabolism | Hypoxia - complications | Platelet-Derived Growth Factor - pharmacology | Pulmonary Artery - drug effects | Rats, Sprague-Dawley | Muscle, Smooth, Vascular - pathology | Animals | Lung - drug effects | Histone Deacetylase Inhibitors - pharmacology | Histone Deacetylases - drug effects | Hydroxamic Acids - therapeutic use | Cell Proliferation - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Hypertension, Pulmonary - etiology | Pulmonary Artery - pathology | Histone Deacetylase 1 - metabolism | genetic | epigenesis | pulmonary | hypertension | Cell proliferation | Divalproex | Care and treatment | Usage | Enzyme inhibitors | Physiological aspects | Research | Valproic acid | Health aspects | Pulmonary hypertension
Journal Article
Circulation, ISSN 0009-7322, 12/2007, Volume 116, Issue 25, pp. 2923 - 2932
Journal Article
Circulation, ISSN 0009-7322, 06/2011, Volume 123, Issue 23, pp. 2681 - 2689
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2004, Volume 44, Issue 9, pp. 1792 - 1800
Journal Article
American Heart Journal, ISSN 0002-8703, 2012, Volume 164, Issue 3, pp. 334 - 342.e1
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2017, Volume 119, Issue 7, pp. 991 - 995
Journal Article